肾移植供体来源游离DNA升高与移植物结局相关
该前瞻性多中心队列纳入1258例肾移植受者,移植后15-60天启动dd-cfDNA监测并随访3年。初始dd-cfDNA升高至中间或高水平与移植物丢失风险分别增加3.70倍和6.36倍独立相关,而持续低水平者排斥和移植物丢失率低。
要点
- dd-cfDNA初始升高至中间或高水平独立预测移植物丢失风险增加。
- 持续低dd-cfDNA水平提示低排斥和低移植物丢失风险人群。
- dd-cfDNA升高时部分患者eGFR仍≥60,提示亚临床损伤。
核心结论
- 初始dd-cfDNA升高超过既定阈值与移植物功能障碍和丢失风险增高独立相关。
- 持续低dd-cfDNA状态患者结局良好。
研究设计与样本
- 前瞻性多中心队列研究(AlloSure注册研究),纳入56个美国中心的1743例成人肾移植受者。
- 本分析纳入1258例移植后15-60天启动dd-cfDNA监测的患者,随访长达3年。
- 采用多状态模型刻画dd-cfDNA状态转换,并用风险回归模型量化与移植物丢失或全因死亡的关联。
主要发现
- 3年内36%患者转换为dd-cfDNA升高状态(中间216例,高233例)。
- 36个月时dd-cfDNA升高者移植物功能障碍显著更常见,尽管升高时42%中间状态和33%高状态患者eGFR≥60 ml/min/1.73 m2。
- 低至升高状态转换与后续移植物丢失强相关:中间状态调整HR 3.70(95%CI 1.38-9.90),高状态调整HR 6.36(95%CI 2.80-14.42)。
- 死亡率在不同dd-cfDNA状态间无差异。
关键数值与推荐
- dd-cfDNA低状态定义为无升高。
- 中间状态定义为0.5%-1.0%且相对变化值≥61%。
- 高状态定义为≥1.0%。
临床怎么用
- 肾移植受者移植后15-60天启动dd-cfDNA监测,初始升高至中间或高水平提示需加强移植物功能监测。
- 持续低dd-cfDNA水平可识别低排斥和低移植物丢失风险人群。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: We assessed whether an initial donor-derived cell-free DNA elevation during routine surveillance was associated with allograft dysfunction and loss in kidney transplant recipients. Intermediate and high donor-derived cell-free DNA states were independently associated with 3.7-fold and 6.4-fold higher risks of allograft loss, respectively. Persistently low donor-derived cell-free DNA levels were associated with low rates of rejection and allograft loss, identifying a low-risk population. BACKGROUND: Although donor-derived cell-free DNA (dd-cfDNA) correlates with histologic rejection and injury severity, its association with long-term graft outcomes has yet to be well established in kidney transplant recipients. We hypothesize that among patients monitored with dd-cfDNA, an initial elevation may be associated with subsequent allograft dysfunction and loss. METHODS: The Kidney Allograft Outcomes AlloSure Registry is a prospective, multicenter cohort of 1743 adult kidney transplant recipients from 56 US centers; this analysis included 1258 patients who initiated dd-cfDNA surveillance 15-60 days post-transplant with up to 3-year follow-up. A multistate model was applied to characterize transitions from a low dd-cfDNA state (no elevations) to intermediate (0.5%-1.0% with ≥61% relative change value) or high (≥1.0%) dd-cfDNA states, and their unadjusted and covariate-adjusted associations with allograft loss or all-cause death were quantified using hazard regression models. RESULTS: Within 3 years, 36% of patients transitioned to an elevated dd-cfDNA state (intermediate n =216; high n =233). Allograft dysfunction by 36 months occurred significantly more often in patients with dd-cfDNA elevations despite preserved allograft function at the time of elevation (eGFR ≥60 ml/min per 1.73 m 2 in 42% of intermediate and 33% of high), consistent with subclinical injury. Transitions from low to elevated dd-cfDNA states were strongly associated with subsequent allograft loss (adjusted hazard ratios, 3.70 [95% confidence interval [CI], 1.38 to 9.90] for intermediate; 6.36 [95% CI, 2.80 to 14.42] for high), while mortality did not differ by dd-cfDNA state. CONCLUSIONS: Initial dd-cfDNA elevations exceeding established thresholds were independently associated with higher risks of allograft dysfunction and loss across both elevation categories, whereas patients who remained in the low dd-cfDNA state experienced favorable outcomes.
引用
- Klein JA, Taber D, Wojciechowski D, et al. Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation. J Am Soc Nephrol. 2026. PMID: 42302101. doi:10.1681/ASN.0000001133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。